MAFLD is defined as hepatic steatosis with metabolic dysregulation, type 2 diabetes mellitus, overweight or obesity, and is characterized by extensive liver lesions, which can progress from isolated steatosis to metabolic dysfunction-associated steatohepatitis (MASH), liver fibrosis, and even HCC
choices range from mesenchymal stem cells and neural stem cells to induced pluripotent stem cell (iPSC)-derived progenitors, each with distinct paracrine profiles and integration potentials
Katturajan R, Nithiyanandam S, Parthasarathy M, Gopalakrishnan AV, Sathiyamoorthi E, Lee J
This section currently applies to GLP-1 medications only
This frequently results in a requirement for injectables, which are more difficult to administer and present their own risks such as site infections or dosing mistakes
Retatrutide: Onderzoek eerst de unieke eigenschappen van deze innovatieve triple agonist (GLP-1, GIP en glucagonreceptor) binnen metabole in-vitro studies